A detailed history of Sg Americas Securities, LLC transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 55,084 shares of RLAY stock, worth $314,529. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55,084
Holding current value
$314,529
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

BUY
$6.23 - $9.51 $343,173 - $523,848
55,084 New
55,084 $390,000
Q4 2023

Jan 12, 2024

BUY
$6.01 - $11.48 $321,889 - $614,857
53,559 Added 139.43%
91,973 $1.01 Million
Q3 2023

Oct 13, 2023

BUY
$8.24 - $12.97 $316,531 - $498,229
38,414 New
38,414 $323,000
Q4 2022

Feb 02, 2023

BUY
$14.16 - $24.02 $75,033 - $127,281
5,299 Added 43.61%
17,450 $261,000
Q3 2022

Oct 31, 2022

SELL
$18.07 - $31.37 $1.3 Million - $2.25 Million
-71,713 Reduced 85.51%
12,151 $272,000
Q2 2022

Jul 29, 2022

BUY
$13.31 - $34.88 $514,311 - $1.35 Million
38,641 Added 85.45%
83,864 $1.41 Million
Q1 2022

Apr 29, 2022

SELL
$20.26 - $32.36 $51,703 - $82,582
-2,552 Reduced 5.34%
45,223 $1.35 Million
Q4 2021

Feb 07, 2022

SELL
$26.0 - $37.03 $1.12 Million - $1.59 Million
-42,965 Reduced 47.35%
47,775 $1.47 Million
Q3 2021

Nov 01, 2021

BUY
$29.75 - $37.99 $1.85 Million - $2.37 Million
62,351 Added 219.63%
90,740 $2.86 Million
Q2 2021

Aug 12, 2021

SELL
$27.5 - $38.19 $85,827 - $119,190
-3,121 Reduced 9.9%
28,389 $1.04 Million
Q1 2021

May 13, 2021

BUY
$32.52 - $61.53 $260,355 - $492,609
8,006 Added 34.06%
31,510 $1.09 Million
Q4 2020

Feb 04, 2021

BUY
$35.51 - $54.03 $834,627 - $1.27 Million
23,504 New
23,504 $977,000

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $686M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.